Blood Pressure Drug Recall

FDA recalls blood pressure medication due to possible risk of cancer

FDA recalls blood pressure medication due to possible risk of cancer

One lot of Losartan tablets, used to treat high blood pressure, has been recalled by Sandoz because it includes "a trace amount" of N-nitrosodiethylamine, commonly referred to as NDEA. Because according to the U.S. Food and Drug Administration, there are some medicines which they have recalled because of the impurity they contained which might cause cancer to its consumer.

Irbesartan tablets manufactured by ScieGen Pharmaceuticals and labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc (GSMS) have been recalled after it's been found out that these medicines contain an impurity. The expiration date on the bottle reads 06/2020.

This lot of the medication was numbered JB8912 and was only distributed on or after October 8, 2018.

All-new Toyota Corolla revealed
The interior was designed, "based on a Sensuous Minimalism concept" which Toyota simplifies as a simple yet sensual vision. USA and Japanese markets get a sportier-looking version called Levin in some Asian markets.

NDMA is an organic chemical used to make liquid rocket fuel and is a byproduct of manufacturing some pesticides and processing fish. The International Agency for Research on Cancer has identified it as a probable human carcinogen. Continue taking losartan potassium hydrochlorothiazide exactly as prescribed until you receive further instructions from him or her. It may be used alone or in combination with other antihypertensive agents.

Patients are advised to speak to their physician or healthcare provider if they happen to take the recalled blood pressure drugs. They should quarantine any remain qualities and return them to the identified reverse distributor.

Patients who are now on the medication are advised to talk to their doctor before stopping use. Printable forms can be downloaded from www.fda.gov/MedWatch/getforms.htm or received by calling 1-800-332-1088. However, it said, no issues have been reported concerning the affected tablets.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.